Glimblist-M 2 Tablet PR is a combination oral antidiabetic medication containing Glimepiride 2mg and Metformin 500mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, functions by stimulating pancreatic beta cells to enhance insulin secretion, thereby improving glycemic control. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production, enhancing peripheral glucose uptake, and improving insulin sensitivity. The synergistic action of these two agents provides effective control of blood glucose levels in patients inadequately managed by diet and exercise alone. Glimblist-M 2 Tablet PR is typically prescribed as part of a comprehensive diabetes management plan, including lifestyle modifications such as diet and physical activity. It is contraindicated in patients with type 1 diabetes, diabetic ketoacidosis, severe renal or hepatic impairment, and conditions predisposing to hypoxia. Common adverse effects may include gastrointestinal disturbances, hypoglycemia, and rare instances of lactic acidosis. Regular monitoring of blood glucose, renal function, and periodic assessment of glycemic control is recommended during therapy. Dose adjustments should be individualized based on therapeutic response and tolerability. Glimblist-M 2 Tablet PR should be used under medical supervision to optimize diabetes management and minimize potential risks.